PICAROS - Acalabrutinib RWE 在西班牙用于 1L CLL (PICAROS)
针对先前未经治疗或第一代 BTKi 不耐受的慢性淋巴细胞白血病患者的非介入队列研究,描述 Acalabrutinib 的一线使用及其在西班牙的真实结果:PICAROS 研究
This is a multicenter non-interventional study (NIS) of patients with CLL treated with first-line acalabrutinib according to routine clinical practice in Spain. It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).
研究概览
地位
条件
详细说明
This is a multicenter, non-interventional study (NIS) based on ambispective (including retrospective and/or prospective) real-world data collection of patients with CLL who received treatment with acalabrutinib for the first time in Spain.
It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).
For the cohort 1, the start of acalabrutinib treatment (index date) was prior to the first site initiation visit. For both cohorts 1 and 2, the clinical decision of starting patient on acalabrutinib has to independently occur prior to the patient inclusion into this study. Patients' eligibility for study inclusion is regardless of their current status of acalabrutinib therapy, for example, patients already deceased or discontinued therapy are still eligible to be included into this study. Patient data will be collected both retrospectively and/or prospectively up to approximately 32 months from the first site initiation visit for cohort 1, and approximately 25 months after the inclusion of the last patient in the cohort 2. For patients who received acalabrutinib therapy and have deceased, only retrospective medical chart review will be conducted.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:AstraZeneca Clinical Study Information Center
- 电话号码:1-877-240-9479
- 邮箱:information.center@astrazeneca.com
学习地点
-
-
Andalusia
-
Almería、Andalusia、西班牙、4009
- 招聘中
- Research Site
-
Córdoba、Andalusia、西班牙、14004
- 招聘中
- Research Site
-
Granada、Andalusia、西班牙、18014
- 招聘中
- Research Site
-
Jaén、Andalusia、西班牙、23007
- 主动,不招人
- Research Site
-
Marbella、Andalusia、西班牙、29603
- 主动,不招人
- Research Site
-
Málaga、Andalusia、西班牙、29010
- 主动,不招人
- Research Site
-
Seville、Andalusia、西班牙、41013
- 招聘中
- Research Site
-
-
Aragon
-
Zaragoza、Aragon、西班牙、50009
- 招聘中
- Research Site
-
Zaragoza、Aragon、西班牙、50009
- 主动,不招人
- Research Site
-
-
Balearic Islands
-
Palma de Mallorca、Balearic Islands、西班牙、7010
- 主动,不招人
- Research Site
-
Palma de Mallorca、Balearic Islands、西班牙、7198
- 主动,不招人
- Research Site
-
-
Basque Country
-
Donostia / San Sebastian、Basque Country、西班牙、20014
- 撤销
- Research Site
-
Galdakao、Basque Country、西班牙、48960
- 撤销
- Research Site
-
-
Canary Islands
-
Las Palmas de Gran Canaria、Canary Islands、西班牙、35016
- 主动,不招人
- Research Site
-
Las Palmas de Gran Canaria、Canary Islands、西班牙、35019
- 主动,不招人
- Research Site
-
San Cristóbal de La Laguna、Canary Islands、西班牙、38320
- 招聘中
- Research Site
-
-
Cantabria
-
Santander、Cantabria、西班牙、39008
- 主动,不招人
- Research Site
-
-
Castille and León
-
Salamanca、Castille and León、西班牙、37007
- 主动,不招人
- Research Site
-
Segovia、Castille and León、西班牙、40002
- 主动,不招人
- Research Site
-
Valladolid、Castille and León、西班牙、47003
- 主动,不招人
- Research Site
-
Valladolid、Castille and León、西班牙、47012
- 主动,不招人
- Research Site
-
-
Castille-La Mancha
-
Guadalajara、Castille-La Mancha、西班牙、19002
- 招聘中
- Research Site
-
Toledo、Castille-La Mancha、西班牙、45004
- 主动,不招人
- Research Site
-
-
Catalonia
-
Barcelona、Catalonia、西班牙、8003
- 主动,不招人
- Research Site
-
Barcelona、Catalonia、西班牙、8025
- 主动,不招人
- Research Site
-
Barcelona、Catalonia、西班牙、8035
- 主动,不招人
- Research Site
-
Barcelona、Catalonia、西班牙、8036
- 主动,不招人
- Research Site
-
Granollers、Catalonia、西班牙、8402
- 主动,不招人
- Research Site
-
L'Hospitalet de Llobregat、Catalonia、西班牙、8908
- 主动,不招人
- Research Site
-
Lleida、Catalonia、西班牙、25198
- 主动,不招人
- Research Site
-
Terrassa、Catalonia、西班牙、8221
- 主动,不招人
- Research Site
-
-
Galicia
-
Ourense、Galicia、西班牙、32005
- 招聘中
- Research Site
-
Santiago de Compostela、Galicia、西班牙、15706
- 主动,不招人
- Research Site
-
Vigo、Galicia、西班牙、36312
- 招聘中
- Research Site
-
-
Madrid
-
Madrid、Madrid、西班牙、28006
- 招聘中
- Research Site
-
Madrid、Madrid、西班牙、28031
- 主动,不招人
- Research Site
-
Madrid、Madrid、西班牙、28034
- 主动,不招人
- Research Site
-
Madrid、Madrid、西班牙、28905
- 主动,不招人
- Research Site
-
Madrid、Madrid、西班牙、28911
- 主动,不招人
- Research Site
-
Madrid、Madrid、西班牙、28040
- 招聘中
- Research Site
-
Madrid、Madrid、西班牙、28041
- 招聘中
- Research Site
-
Madrid、Madrid、西班牙、28046
- 招聘中
- Research Site
-
Majadahonda、Madrid、西班牙、28222
- 主动,不招人
- Research Site
-
-
Murcia
-
El Palmar、Murcia、西班牙、30120
- 主动,不招人
- Research Site
-
Murcia、Murcia、西班牙、30008
- 招聘中
- Research Site
-
-
Principality of Asturias
-
Oviedo、Principality of Asturias、西班牙、33011
- 主动,不招人
- Research Site
-
-
Valencia
-
Alicante、Valencia、西班牙、3010
- 招聘中
- Research Site
-
Valencia、Valencia、西班牙、46010
- 主动,不招人
- Research Site
-
Valencia、Valencia、西班牙、46014
- 主动,不招人
- Research Site
-
Valencia、Valencia、西班牙、46026
- 主动,不招人
- Research Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
The study aims to include approximately 315 patients in the cohort 1 and 103 patients in the cohort 2 who started acalabrutinib for the first time for the treatment of their CLL. To minimize selection biases, all patients (alive or deceased) identified on acalabrutinib will be eligible for inclusion into the study. These patients will be included from approximately 50 hospitals distributed throughout Spain.
描述
Inclusion Criteria:
- Age ≥18 years old at starting acalabrutinib treatment.
- Diagnosis of CLL.
- Start of acalabrutinib treatment (index date) as per the CLL SmPC:
- in treatment-naïve CLL patients or those switching in first-line between first-generation BTK inhibitor to acalabrutinib due to intolerance in absence of progression according to routine clinical practice within the year before the first site initiation visit (cohort 1).
- in treatment-naïve CLL patients for the fixed-duration treatment combination of acalabrutinib plus venetoclax (with or without obinutuzumab) according to routine clinical practice from the EMA approval (i.e., 2 June 2025) (cohort 2).
Decision to administer acalabrutinib must be made and documented prior to inclusion into the study and must follow local clinical practice.
- Informed consent (for alive patients).
Exclusion Criteria:
- Enrolled in any clinical trial during acalabrutinib treatment.
- Patients who are unable to understand the study and its questionnaires due to insufficient knowledge of the Spanish language or their health status.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:OTHER
队列和干预
团体/队列 |
|---|
|
Cohort 1
Patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit as per routine clinical practice, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression. |
|
Cohort 2
Patients with first-line fixed-duration acalabrutinib use with venetoclax in routine clinical practice. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1).
大体时间:24 months after treatment initiation (cohort 1).
|
Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1). In addition to this outcome measured in the overall cohort, it will also be assessed by the following factors:
|
24 months after treatment initiation (cohort 1).
|
|
Real-world overall response rate (rwORR) achieved until the end of the observational period for first-line fixed duration acalabrutinib therapy (cohort 2)
大体时间:From fixed-duration acalabrutinib start to the start date of a subsequent line therapy or study end date (cohort 2), assessed up to 25 months after the inclusion of the last patient in the cohort 2.
|
rwORR (i.e., the proportion of patients that achieved complete or partial response) achieved until the end of the observational period for first-line fixed-duration acalabrutinib therapy as assessed by the treating physician (cohort 2). Complete response may include complete response, complete response with incomplete marrow recovery, or unconfirmed complete response (marrow biopsy not performed). Partial response may include partial response, or partial response with lymphocytosis. The rwORR will be assessed by the treating physician in routine clinical practice, including the use or not of the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. The end of observational period for first-line fixed-duration combinations of acalabrutinib is defined as the start date of a subsequent line therapy or study end date, whichever comes first. |
From fixed-duration acalabrutinib start to the start date of a subsequent line therapy or study end date (cohort 2), assessed up to 25 months after the inclusion of the last patient in the cohort 2.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Acalabrutinib±venetoclax doses (cohorts 1 and 2).
大体时间:At start date and subsequent dose adjustments during acalabrutinib±venetoclax administration assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
Acalabrutinib±venetoclax doses (e.g., starting does and dose adjustments), overall (cohorts 1 and 2) and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). In cohort 2, doses (e.g., starting dose, dose adjustments, maximum dose achieved) and reasons for changes within the acalabrutinib±venetoclax fixed-duration regimen will also be described globally and for each drug separately, as well as the time to reach the maximal dose. |
At start date and subsequent dose adjustments during acalabrutinib±venetoclax administration assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
|
Patients with acalabrutinib±venetoclax dose adjustments (n, %), temporary interruptions (n, %), and permanent discontinuations (n, %) (cohorts 1 and 2).
大体时间:From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
Acalabrutinib±venetoclax dose adjustments, temporary interruptions, and permanent discontinuations, overall (cohorts 1 and 2) and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). In patients with regimen modifications within cohort 2, the proportion of patients with these regimen modifications and the time from treatment initiation to the regimen modification within same line therapy prior to progression (e.g., treatment duration and number of cycles prior to the modification, and reason for the modification). In cohort 2, temporary interruptions, permanent discontinuations, and their reasons for changes within the acalabrutinib±venetoclax fixed-duration regimen will also be described globally and for each drug separately, as well as the proportion of patients requiring dose reductions after achieving maximum dose. |
From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
|
Treatment duration in months (cohorts 1 and 2).
大体时间:From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
Treatment duration (cohorts 1 and 2), overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). In cohort 2, also median number of completed cycles and the proportion of patients who complete 14 cycles. Baseline patient characteristics associated with treatment duration in multivariate analyses, overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). |
From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
|
Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib (cohort 1).
大体时间:From acalabrutinib start to acalabrutinib end, assessed up to 32 months of prospective study follow-up (cohort 1).
|
Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib, overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1). The PDC will be based on data available on acalabrutinib treatment in pharmacy records, and defined as the percentage of days a patient has the medication available in a given period of time: PDC (%)=(No.days covered)/(No.days of interest)×100 |
From acalabrutinib start to acalabrutinib end, assessed up to 32 months of prospective study follow-up (cohort 1).
|
|
TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause) (cohorts 1 and 2).
大体时间:From the date of first dose of acalabrutinib to first dose of next CLL treatment or death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause [i.e. deaths are not censored]), overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). |
From the date of first dose of acalabrutinib to first dose of next CLL treatment or death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
|
OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause) (cohorts 1 and 2).
大体时间:From the date of first dose of acalabrutinib to death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause), overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). |
From the date of first dose of acalabrutinib to death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
|
Adverse events that lead to acalabrutinib±venetoclax dose changes, temporary interruptions, or permanent discontinuation; that are considered serious during acalabrutinib±venetoclax treatment; and events of clinical interest (cohorts 1 and 2).
大体时间:From acalabrutinib±venetoclax start to acalabrutinib±venetoxlax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
Adverse events that lead to acalabrutinib±venetoclax dose changes, temporary interruptions, or permanent discontinuation. Adverse events that are considered serious (including fatal events) during acalabrutinib±venetoclax treatment, globally and treatment related (when available). Events of clinical interest (atrial fibrillation, hypertension, bleeding, infections, ventricular arrhythmias, hepatotoxicity, secondary primary malignancies, cytopenia, and pneumonitis) during acalabrutinib treatment, globally and treatment related (when available). They will be described overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). |
From acalabrutinib±venetoclax start to acalabrutinib±venetoxlax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- D8221R00003
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD 共享时间框架
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共享访问标准
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.